Inotiv, Inc. – FDA 483, Jul 14, 2022
An FDA inspection of Inotiv, Inc. in Mount Vernon, IN, a nonclinical laboratory, revealed a significant observation regarding the study director's failure to ensure the quality and integrity of nonclinical laboratory studies. Specifically, the study director did not adequately investigate unforeseen circumstances affecting data quality, such as low dose recovery, nor did deviation reports consistently determine root causes or document corrective actions. This indicates issues with data integrity and quality control in their nonclinical studies.
ID · 56433f88-54ec-4ee1-ae40-0de975f41344
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.